Cargando…
Stellarex drug‐coated balloon for treatment of femoropopliteal arterial disease—The ILLUMENATE Global Study: 12‐Month results from a prospective, multicenter, single‐arm study
OBJECTIVES: The purpose of this study was to assess the safety and performance of Stellarex Drug‐coated balloon (DCB). BACKGROUND: DCB coatings differ in excipients, paclitaxel dose, and coating morphologies. Due to these differences, a class effect with DCBs has not been demonstrated. Consequently,...
Autores principales: | Schroë, Herman, Holden, Andrew H., Goueffic, Yann, Jansen, Shirley J., Peeters, Patrick, Keirse, Koen, Ito, Wulf, Vermassen, Frank, Micari, Antonio, Blessing, Erwin, Jaff, Michael R., Zeller, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836976/ https://www.ncbi.nlm.nih.gov/pubmed/29086462 http://dx.doi.org/10.1002/ccd.27348 |
Ejemplares similares
-
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies
por: Krishnan, Prakash, et al.
Publicado: (2017) -
Two‐year results of a low‐dose drug‐coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first‐in‐human study
por: Schroeder, Henrik, et al.
Publicado: (2015) -
Paclitaxel exposure: Long‐term safety and effectiveness of a drug‐coated balloon for claudication in pooled randomized trials
por: Schneider, Peter A., et al.
Publicado: (2020) -
Drug-Coated Balloon Treatment of Femoropopliteal Lesions Typically Excluded From Clinical Trials: 12-Month Findings From the IN.PACT Global Study
por: Ansel, Gary M., et al.
Publicado: (2018) -
Individual patient data meta‐analysis of patients treated with a heparin‐bonded Viabahn in the femoropopliteal artery for chronic limb‐threatening ischemia
por: Groot Jebbink, Erik, et al.
Publicado: (2022)